Targeting KDM4A-AS1 represses AR/AR-Vs deubiquitination and enhances enzalutamide response in CRPC. Zhang B, Zhang M, Yang Y, Li Q, et al. Oncogene 2022;41:387-399.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Zhang B, Zhang M, Yang Y, Li Q, et al. Targeting KDM4A-AS1 represses AR/AR-Vs deubiquitination and enhances enzalutamide response in CRPC. Oncogene 2022;41:387-399.
PMID: 34759344